Adeona Pharmaceuticals, www.adeonapharma.com – the pharmaceutical company with particular emphasis on central nervous system diseases – whose primary strategy is licensing clinical-stage drugs that have demonstrated efficacy and then developing them further – reported today obtaining 100% enrollment in Part 2 of the CopperProof-2 clinical study of a new oral zinc cysteine preparation for Alzheimer’s called Zinthionein.
Zinthionein is AEN’s proprietary, single-dose oral formulation of zinc cysteine, which is characterized by notable sustained release and gastro-retentive advantages, as well as vastly superior bioavailability of zinc, compared to the extant FDA-approved inorganic zinc acetate.
Part 2 of this prospective, randomized and double-blind trial was designed as a comparator study involving 60 subjects with Alzheimer’s and mild cognitive impairment.
A randomized 50:50 split for either Zinthionein or the matching placebo is implemented over a 3-6 month interval, after which time standard clinical testing for Alzheimer’s via serum measurements of zinc/copper is performed to validate efficacy.
Senior VP of R&D for AEN, David A. Newsome, M.D., F.A.R.V.O., buzzed with excitement at the progress being made in this clinical study, noting in particular how Zinthionein is a vehicle with the potential to drive massive revenues for the Company and its shareholders.
Newsome projected March 2011 results for Part 2 of the CopperProof-2 study, noting the absence of a single case of adverse side effects or dropouts in the study thus far, and indicating that Zinthionein could soon be readily available as a prescription medical food.
Newsome characterized the enrollment report as a “milestone” which would allow for a greater quantum of energy and resources to be applied to GMP production, product packaging and pre-commercialization work in order to get the product ready for an extremely eager market.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment